Phase 2 Ovarian Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 to 70 years old who are female.
• People who have been diagnosed through laboratory testing (tissue or cell analysis) with epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, where the cancer came back within less than 6 months after completing a platinum-based chemotherapy treatment.
• People who have at least one tumour that can be measured using standard imaging guidelines (called RECIST 1.1).
• People whose cancer has tested positive for a mutation in an HRR (homologous recombination repair) gene, confirmed through a tissue or blood test.
• People with a general health and activity level rated as 0 or 1 on the ECOG scale, meaning largely able to carry out normal daily activities (confirm with trial site).
• People whose blood test results meet specific minimum levels for red blood cells, white blood cells, and platelets, without having had a blood transfusion in the 14 days before testing (confirm with trial site for exact values).
• People whose liver and kidney function blood test results fall within acceptable ranges as defined by the trial (confirm with trial site for exact values).
• People whose blood clotting test results are within acceptable limits, or who are on blood-thinning medication with clotting levels within the expected range for that treatment.
• People without serious heart, lung, liver, or kidney disease.
• People who are not pregnant (confirmed by a blood pregnancy test within 7 days before joining) and who are willing to use appropriate contraception during the trial and for 8 weeks after the last dose of study medication.
• People with an estimated life expectancy of at least 12 weeks.
• People who are willing and able to sign a consent form and follow the trial schedule and procedures.

Who may not be able to join:

• People who are currently taking part in another clinical trial involving an experimental drug.
• People with a known allergy or sensitivity to fluzoparib, or to other drugs with a similar chemical structure.
• People with a known allergy or sensitivity to adebrelimab, or to other drugs with a similar chemical structure.
• People who are unable to swallow tablets or capsules, or who have a digestive condition that could affect how the body absorbs the study medications, such as uncontrolled nausea, vomiting, bowel obstruction, or malabsorption.
• People who have previously been treated with immune checkpoint inhibitor drugs (a type of immunotherapy).
• People who currently have, or have a history of, an active autoimmune disease (a condition where the immune system attacks the body), with some exceptions — including vitiligo, childhood asthma or allergies that no longer require treatment, autoimmune-related underactive thyroid managed with a stable hormone replacement dose, or type 1 diabetes managed with a stable insulin dose.
• People with a history of immune system deficiency, a positive HIV test, other inherited or acquired immune disorders, or a history of organ transplant or bone marrow transplant from a donor.
• People with unstable ongoing health conditions, such as high blood pressure that cannot be controlled with medication (readings at or above 140/90 mmHg), or serious irregular heart rhythms.
• People with a current or past history of certain lung conditions, including idiopathic pulmonary fibrosis, interstitial lung disease, pneumoconiosis, radiation-related lung damage, organising pneumonia, drug-induced lung disease, or active pneumonia seen on a recent CT scan.
• People with poorly controlled heart conditions, including significant heart failure, unstable chest pain (angina), a heart attack within the past year, significant abnormal heart rhythms requiring treatment, or a specific heart electrical measurement (QTc) above 470 milliseconds.
• People who are pregnant, breastfeeding, or planning to become pregnant during the study treatment period.
• People the trial investigators consider unsuitable for participation for other medical reasons.

Important: Always verify eligibility with the trial site directly before applying.